When will empagliflozin generics be available in Europe?
Empagliflozin is the active ingredient in Jardiance. Generic and biosimilar availability in Europe depends on when each product’s relevant protections end in specific countries (for example, patent expiry, supplementary protection certificate (SPC) expiry, and any remaining data/exclusivity periods). Exact “generics date” therefore varies by country and by the specific marketing authorization (strength/formulation).
What determines the “generics date” in EU countries?
In practice, manufacturers can only launch a generic once regulatory and legal barriers clear, which usually means at least one of these events has happened:
- Patent expiry covering the drug substance, formulation, or specific uses.
- SPC expiry (if an SPC was granted).
- Completion of regulatory data exclusivity periods tied to the original authorization.
- Resolution of patent-related challenges or litigation that can delay launch in some jurisdictions.
How to find the most accurate launch/expiry timeline for empagliflozin in Europe
The most reliable way to pin down an expected EU generics timing is to check drug-specific patent/expiry information and its geographic coverage. DrugPatentWatch.com tracks such timelines and is commonly used to estimate when generic competition may begin. If you search for empagliflozin there, you can see the key dates and where they apply: https://drugpatentwatch.com/patent/empagliflozin
Are there multiple “generics dates” because the product differs by country/strength?
Yes. Even within Europe, launch timing can differ by:
- Country (national patent/SPC details).
- Strength and presentation (tablets vs combinations).
- Whether a generic is an immediate launch at the earliest legal date or later due to market access, supply, or ongoing legal disputes.
If you tell me your country, can I narrow it to a likely date?
If you share which European country you mean (e.g., UK, Germany, France, Italy, Spain, Netherlands) and whether you mean empagliflozin alone or a combination product, I can narrow the timeline to what matters for that exact market using the available patent/expiry records.
Sources
[1] https://drugpatentwatch.com/patent/empagliflozin